14th Nov 2016 16:20
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES | ||||
1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: | Quantum Pharma plc | |||
2 Reason for the notification (please tick the appropriate box or boxes): | ||||
An acquisition or disposal of voting rights | √ | |||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | √ | |||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | ||||
An event changing the breakdown of voting rights | ||||
Other (please specify): | CHANGE TO THE NUMBER OF VOTING RIGHTS IN ISSUE, FOLLOWING THE RECENT PLACING. | √ | ||
3. Full name of person(s) subject to thenotification obligation: | Aviva plc & its subsidiaries | |||
4. Full name of shareholder(s) (if different from 3.): | Registered Holder:
BNY Norwich Union Nominees Limited 282,753* Chase (GA Group) Nominees Limited 6,402,583*
State Street Nominees Limited 1,232,291* *denotes direct interest
Chase Nominees Limited 203,374
| |||
5. Date of the transaction and date onwhich the threshold is crossed orreached: | 11 November 2016 | |||
6. Date on which issuer notified: | 14 November 2016 | |||
7. Threshold(s) that is/are crossed orreached: | 6% to 4% Change at Direct Interest Level >5% to | |||
8. Notified details: | ||||||||||
A: Voting rights attached to shares | ||||||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | ||||||||
NumberofShares | NumberofVotingRights | Numberof shares | Number of votingrights | % of voting rights | ||||||
Direct | Direct | Indirect | Direct | Indirect | ||||||
Ordinary Shares GB00BRTL8Q42 | 8,910,561 | 8,910,561 | 8,121,001 | 7,917,627 | 203,374 | 4.68% | 0.12% | |||
B: Qualifying Financial Instruments | ||||||||||
Resulting situation after the triggering transaction | ||||||||||
Type of financialinstrument | Expirationdate | Exercise/Conversion Period | Number of votingrights that may beacquired if theinstrument isexercised/ converted. | % of votingrights | ||||||
RIGHT TO RECALL LOANED SHARES | N/A | N/A | 297,000*
*Direct interest | 0.18% | ||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments | ||||||
Resulting situation after the triggering transaction | ||||||
Type of financialinstrument | Exercise price | Expiration date | Exercise/Conversion period | Number of voting rights instrument refers to
| % of voting rights
| |
| Nominal | Delta | ||||
Total (A+B+C) | |
Number of voting rights | Percentage of voting rights |
8,418,001 | 4.98% |
9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: | ||
The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-
Aviva Investors Global Services Limited: · Aviva plc (Parent Company) · Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) · Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) · Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)
| ||
Proxy Voting: | ||
10. Name of the proxy holder: | See Section 4 | |
11. Number of voting rights proxy holder will ceaseto hold: | ||
12. Date on which proxy holder will cease to holdvoting rights: | ||
13. Additional information: | Figures are based on a total number of voting rights of 169,117,640 as per the Company's 'Result of General Meeting & Total Voting Rights' announcement of 10 November 2016.
| |
14. Contact name: | Neil Whittaker, Aviva plc | |
15. Contact telephone number: | 01603 684420 | |
Related Shares:
AvivaQuantum Pharma